- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Merge posts big revenue gain
Connectivity firm Merge Technologies reported 55% revenue growth in its first quarter as a public company. The Milwaukee-based software developer credited new product sales and an expanded sales force for the strong performance.For the period
Connectivity firm Merge Technologies reported 55% revenue growth in its first quarter as a public company. The Milwaukee-based software developer credited new product sales and an expanded sales force for the strong performance.
For the period (end-March), Merge posted revenues of $2.6 million, compared with $1.7 million in 1997. The company had a net loss of $56,000, compared with a net loss of $45,000 in the same period last year.
In quarterly highlights, Merge shipped two beta units of its CD-based MergeARK archiving offering. The firm also has been granted a patent for CaseWorks, the first product in Merges line of Networked Image Management offerings, which the company believes will facilitate the development of electronic patient records. CaseWorks is a radiology work-flow management tool that uses a MergeReader hand-held unit to mark films that should be included in a patients EPR. Merge expects CaseWorks to begin shipping in mid-1998.
Since Merges debut on the NASDAQ SmallCap Market in January, the companys stock has seen its share price climb to a high of $7, before falling below its initial public offering price of $6. As of May 4, Merge shares closed at $5.03, down 16.2% from the IPO price.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
